Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Kissei Pharmaceutical

キッセイ薬品工業

4547 · TSE · Pharmaceutical · 4 articles

Financials Consolidated

Revenue¥97.4bn+10.3% year on yearConsolidated · FY3/26

Ordinary profit−¥1.16bnConsolidated · FY3/26

Net profit¥13.8bn+15.2% year on yearConsolidated · FY3/26

Dividend per share¥160.00FY3/26

Performance over time

Revenue
¥65.4bnFY3/22
¥67.5bnFY3/23
¥75.6bnFY3/24
¥88.3bnFY3/25
¥97.4bnFY3/26
Ordinary profit
¥562mFY3/22
¥598mFY3/23
¥6.14bnFY3/24
¥6.97bnFY3/25
−¥1.16bnFY3/26
Net profit (attributable)
¥12.9bnFY3/22
¥10.5bnFY3/23
¥11.2bnFY3/24
¥12.0bnFY3/25
¥13.8bnFY3/26
Op. cash flow
¥1.53bnFY3/22
−¥6.68bnFY3/23
−¥1.68bnFY3/24
¥6.52bnFY3/25
−¥1.49bnFY3/26

People & pay

Employees, whole group1,786 peopleFY3/26

Employees, parent company (non-consolidated)1,297 peopleFY3/26

Average salary¥7.98mFY3/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitNet profit (attributable)EPSDividendTotal assetsNet assetsOp. cash flow
FY3/26¥97.4bn+10.3% year on year−¥1,162m¥13.8bn¥331.54¥160.00¥275bn¥232bn−¥1.49bn
FY3/25¥88.3bn+16.9% year on year¥6,974m¥12.0bn¥274.21¥100.00¥244bn¥210bn¥6.52bn
FY3/24¥75.6bn+12.0% year on year¥6,142m¥11.2bn¥246.61¥82.00¥261bn¥221bn−¥1.68bn
FY3/23¥67.5bn+3.2% year on year¥598m¥10.5bn¥228.31¥80.00¥221bn¥195bn−¥6.68bn
FY3/22¥65.4bn¥562m¥12.9bn¥280.20¥56.00¥238bn¥202bn¥1.53bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100YFN3 · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4547

Tokyo Brief coverage

All articles loaded · 4 shown

Buybacks

Authorised and executed under the company’s current programmes.

1 programme · data through

The line marks how much of the buying window has passed; a bar beyond it is buying ahead of pace.

Buybacks
ResolutionProgress by companyFiling
Runs to 31 Dec 202613% of yen limit used¥799m / ¥6bn · 200k / 1.3m shares74% of the buying window to 31 Dec 2026 has passedFiled  — filing S100ZDRA

5% holders

Latest disclosed holders and exits below 5%.

1 holder · data through

5% holders
HolderStakeChangePurposeFiling
ブランデス・インベストメント・パートナーズ・エル・ピー6.23%+1.08 ppAsset manager / trustAcquisition on behalf of customers for investment purposesMachine translated
Original (Japanese)投資目的による顧客に代理しての取得
Filed  — filing S100ZBY2

AGM votes

This season’s shareholder voting results.

1 meeting · data through

AGM votes
ProposalApprovalResultFiling
Appropriation of surplus
Original (Japanese)剰余金の処分の件
97.92%Votes cast: 99.93%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 神澤 陸雄
68.09%Votes cast: 69.49%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 宮澤 敬治
74.34%Votes cast: 75.86%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 高山 哲
85.57%Votes cast: 87.32%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 北原 孝秀
85.47%Votes cast: 87.23%ApprovedFiled  — filing S100YLEE
Show 10 more meetings (15 total)
AGM votes
ProposalApprovalResultFiling
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 野明 浩史
85.59%Votes cast: 87.35%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 降簱 喜男
85.57%Votes cast: 87.33%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 駒村 孝幸
89.07%Votes cast: 90.90%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 柳 伸子
89.12%Votes cast: 90.95%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 清水 重孝
68.24%Votes cast: 69.64%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 内川 小百合
86.57%Votes cast: 88.35%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 大月 良則
86.57%Votes cast: 88.35%ApprovedFiled  — filing S100YLEE
Election of 12 directors
Original (Japanese)取締役12名選任の件
· 髙野 良子
90.18%Votes cast: 92.03%ApprovedFiled  — filing S100YLEE
Election of 1 auditor
Original (Japanese)監査役1名選任の件
· 菊池 伸次
83.65%Votes cast: 85.37%ApprovedFiled  — filing S100YLEE
Matter of election of 1 alternate statutory auditorMachine translated
Original (Japanese)補欠の監査役1名選任の件
· 久保田 明雄
97.92%Votes cast: 99.93%ApprovedFiled  — filing S100YLEE

Approval is the ratio the company states (usually of the voting rights of shareholders present); votes cast are for ÷ (for + against + abstain).

† Percentage of votes cast; company did not state a ratio.

† Company-stated ratio differs from tallied votes.

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

6 fiscal years · data through

Balance-sheet value
¥36.5bnFY3/22
¥30.8bnFY3/23
¥33.4bnFY3/24
¥28.2bnFY3/25
¥32.0bnFY3/26
Sale proceeds
—FY3/22
¥0.03bnFY3/23
¥3.18bnFY3/24
¥3.15bnFY3/25
¥4.59bnFY3/26

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 202618¥32bn13.82%3¥4.59bnFiled  — filing S100YFN3
Show 5 more fiscal years (6 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 202519¥28.2bn13.42%3¥3.15bnFiled  — filing S100W31F
31 Mar 202420¥33.4bn15.10%3¥3.18bnFiled  — filing S100TRIA
31 Mar 202322¥30.8bn15.82%4¥25mFiled  — filing S100R0YK
31 Mar 202226¥36.5bn18.05%——Filed  — filing S100OOE8
31 Mar 202126¥37.3bn16.96%——Filed  — filing S100LO0H

Fund positioning

Current holdings disclosed by tracked funds.

23 funds · data through

Held by 23 tracked funds; largest weight 0.28%. Holdings as of 31 Jul 2026–20 Nov 2026.

Show 13 more funds (23 total)